Pixabay/Thanasis Papazacharias: Covid-19 research with Evosep One
The global emergence of novel coronavirus disease 2019 (COVID-19) has underlined the requirement for rapid assays with high sensitivity and specificity for detection of infection and further to understand the molecular complexity of the disease.
We developed a flexible workflow that allows for high throughput analysis and reliable quantification of blood based proteomes. The workflow was applied to a two part study that was designed to (i) establish reference ranges of plasma proteins (ii) differential protein expression in individuals that were Covid-19 positive, Covid-19 negative and healthy controls.
DIA-MS data acquisition was established on Exploris 480 (Thermo), coupled to an Evosep One. 664 native plasma samples were processed using i7 automation workstation (Beckman-Coulter) and analyzed using Evosep 60 sample/ day workflow.
Our streamlined workflow supported reliable quantification of proteins covering a broad dynamic range. Cluster analysis revealed protein signatures that clearly distinguished individuals who were diagnosed as Covid-19 positive vs healthy controls. It was also possible to identify a panel of proteins predictive of mortality.
Presenter: Angela McArdle, Project Scientist, Cedars-Sinai
We have developed and optimised targeted LC-MS methods to detect SARS-COV-2 in patient samples. Using an Evosep One instrument coupled to a QExactive HF, we can show high sensitivity for specific SARS-COV-2 peptides. We further multiplexed the assay by targeting peptides of other respiratory viruses such as FluA and FluB.
The Evosep system showed great robustness even when 300 samples with complex matrices such as saliva were analysed per day.
Presenter: Matthias Trost, Professor of Proteomics, Newcastle university
